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Abstract
The current literature on the role of interleukin (IL)‑2 in memory CD8+ T‑cell differentiation indicates a significant contribution of IL‑2 during primary and also secondary expansion of CD8+ T‑cells. IL‑2 seems to be responsible for optimal expansion and generation of 
effector functions following primary antigenic challenge. As the magnitude of T‑cell expansion 
determines the numbers of memory CD8+ T‑cells surviving after pathogen elimination, these events 
influence memory cell generation. Moreover, during the contraction phase of an immune response 
where most antigen‑specific CD8+ T‑cells disappear by apoptosis, IL‑2 signals are able to rescue 
CD8+ T‑cells from cell death and provide a durable increase in memory CD8+ T‑cell counts. At 
the memory stage, CD8+ T‑cell frequencies can be boosted by administration of exogenous IL‑2. 
Significantly, only CD8+ T‑cells that have received IL‑2 signals during initial priming are able to 
mediate efficient secondary expansion following renewed antigenic challenge. Thus, IL‑2 signals 
during different phases of an immune response are key in optimizing CD8+ T‑cell functions, 
thereby affecting both primary and secondary responses of these T‑cells.
Introduction
Typical T‑cell receptor (TCR)αβ T‑cells are derived from precursors that migrate to the thymus 
where they undergo a series of selection and maturation processes termed positive and negative 
selection.1 During positive selection, T‑cells with newly‑arranged TCRαβ complexes are tested 
for their ability to receive survival signals via TCR contact with self‑peptides bound to major 
histocompatibility complex (MHC) molecules expressed on cortical epithelium: cells with low 
but significant reactivity for self‑peptide/MHC ligands are selected for survival while low‑affinity 
cells die in situ, thus selecting only T‑cells with functional TCRs. Conversely, through contact 
with antigen on bone marrow (BM)‑derived dendritic cells (DCs), negative selection eliminates 
T‑cells with high affinity for self‑peptide/MHC molecules, thus ensuring the deletion of potentially 
auto‑reactive T‑cells. At the end of these selection processes, mature CD4+ and CD8+ T‑cells are 
generated and subsequently released into the bloodstream for export to the secondary lymphoid 
organs. Despite the fact that these cells are selected on self‑peptide/MHC molecules in the thymus, 
the cells have not yet seen foreign antigens and are thus immunologically naïve.
Post‑thymic naïve T‑cells recirculate continuously between blood and lymph through the 
lymphoid tissues and remain in interphase, rarely if ever dividing.2,3 Activation of naïve T‑cells 
occurs in the secondary lymphoid organs, such as lymph nodes and spleen, upon encounter with 
their cognate antigen in the form of peptides bound to MHC molecules presented by mature 
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e. 
N
ot
 fo
r D
ist
rib
ut
io
n
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antigen‑presenting cells (APCs) that express costimulatory molecules, notably DCs.4 Upon 
activation, T‑cells undergo vigorous clonal expansion and differentiate into effector cells which 
then home to the site of infection. These primed cells can directly exert their effector functions 
upon TCR engagement without the necessity for costimulatory signals; effector CD8+ cells kill 
pathogen‑infected cells whereas activated CD4+ cells provide “help” for CD8+ cell differentiation 
or induce B‑cells to produce high‑affinity antibodies.
At the end of the expansion of antigen‑specific T‑cells, which usually occurs after the pathogen has 
been eliminated, the immune response undergoes a contraction phase where most antigen‑specific 
effector T‑cells die via apoptosis.5,6 However, a minority (about 5%) of antigen‑specific T‑cells survives 
to become long‑lived memory cells.7,8 These cells are resting cells but, unlike naïve T‑cells, memory 
cells display certain surface markers (such as a high density of CD44 in mice) which distinguish these 
cells from naïve T‑cells. Notably, unmanipulated normal mice contain significant numbers of cells 
with high expression of CD44 (CD44hi), thus closely resembling memory T‑cells found after delib‑
erate antigen priming.8,9 These CD44hi “memory‑phenotype” (MP) cells account for about 10‑15% 
of total T‑cells in young mice but become a majority population in old age; MP cells are thought to 
represent the descendents of T‑cells reacting to ubiquitous environmental or self‑antigens.10
Both naïve and memory T‑cells are maintained in fairly stable numbers during normal 
steady‑state conditions (reviewed in ref. 9). The homeostatic processes that govern T‑cell survival 
are complex, but contact with two cytokines, IL‑7 and IL‑15, with or without TCR signals from 
contact with self‑peptide/MHC ligands are of particular importance. For naïve T‑cells, these 
cells are maintained through constant low‑level signals via contact with IL‑7 and self‑peptide/
MHC molecules (MHC‑I for CD8+ and MHC‑II for CD4+ cells).11,12 For most memory (and 
MP) CD8+ T‑cells, by contrast, homeostasis depends on contact with both IL‑7 and IL‑15, while 
TCR contact with self‑peptide/MHC‑I ligands is relatively unimportant.13‑15 Similar to their CD8+ 
counterparts, memory CD4+ cells also require signals from IL‑7 and IL‑15 and do not depend on 
contact with MHC (MHC‑II) molecules.16‑18 Typical memory and MP cells are resting cells which 
divide intermittently through contact with IL‑15, the density of CD122, the receptor for IL‑15, 
being higher on memory cells than naïve cells.19 It should be mentioned that about one‑third of MP 
cells are activated cells; these cells ignore cytokines and seem to be engaged in chronic responses 
to unknown self‑peptide/MHC ligands, both for CD4+ and CD8+ cells.20,21
IL‑7 and IL‑15 belong to the family of common gamma chain (γc) cytokines, which share us‑
age of the γc receptor (also called CD132). This family also includes another cytokine that plays 
a central role in T‑cell homeostasis, namely IL‑2. This cytokine exerts complex effects on typical 
mature T‑cells and is also primarily responsible for the survival of CD4+ CD25+ T regulatory cells 
(Tregs).22 IL‑2 is a 15 kDa short‑chain four α‑helical bundle cytokine and is produced mainly 
by activated CD4+ T helper cells, although activated CD8+ T‑cells, natural killer (NK) cells, NK 
T‑cells and DCs stimulated with microbial products are also able to secrete IL‑2, albeit in low 
amounts.23‑29 IL‑2 acts in an autocrine or paracrine fashion by binding to IL‑2 receptors (IL‑2Rs).30 
High‑affinity IL‑2Rs are trimeric receptors consisting of IL‑2Rα (CD25), IL‑2Rβ (CD122) and 
the γc chain (Fig. 1); these receptors bind strongly to IL‑2 with a dissociation constant (Kd) of 
about 10-11 M.31‑33 Trimeric IL‑2Rs are found on Tregs as well as on recently‑activated normal 
T‑cells.30,34 In addition to trimeric IL‑2Rs, IL‑2 can also bind to dimeric IL‑2Rs consisting of 
CD122 and γc, albeit with a 100‑fold lower affinity (Kd ∼10-9 M). Dimeric IL‑2Rs bind IL‑15 in 
addition to IL‑2 (Fig. 1) and are found at high levels on resting memory and MP CD8+ cells as 
well as NK cells and at low but significant levels on naïve CD8+ cells. Notably, CD122 and γc are 
responsible for mediating intracellular signaling whereas CD25 confers high‑affinity binding to 
IL‑2 but does not directly contribute to signal transduction.31
Below, we will review the role of IL‑2 in CD8+ T‑cell responses in vivo; the in vitro actions of 
IL‑2 have been reviewed extensively elsewhere.30‑33 In particular, we will discuss the contribution 
of IL‑2 to the different phases of a CD8+ T‑cell response, starting with CD8+ cell activation and 
expansion, followed by the contraction phase and then the memory phase. During each of these 
different stages, IL‑2 has a decisive effect on CD8+ cells. Thus, by controlling initial T‑cell expansion 
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3The Role of Interleukin-2 in Memory CD8 Cell Differentiation
and differentiation during the primary response, IL‑2 influences both the numbers and functions 
of the cells that survive to become long‑lived memory cells.35
IL‑2 Signals During Priming Lead to Q ualitative and Q uantitative 
Differences in CD8+ T‑Cell Responses
Once naïve T‑cells encounter their cognate antigen presented by mature APCs and receive 
TCR and costimulatory signals, they become activated and begin to proliferate. Activation and 
proliferation of T‑cells induces many changes, including the upregulation of CD25 and CD122, 
thus leading to expression of trimeric high‑affinity IL‑2Rs (Fig. 2). At the same time, activated 
T‑cells, especially CD4+ cells, start producing IL‑2. Via synthesis of high‑affinity IL‑2Rs, activated 
T‑cells, including CD8+ cells, are highly sensitive to IL‑2.
The contribution of IL‑2 signals to primary CD8+ T‑cell responses has been studied using IL‑2‑ 
or IL‑2R‑deficient mice (Table 1). Activation, expansion and primary effector functions of CD8+ 
T‑cells were tested in IL‑2–/– mice following infection with lymphocytic choriomeningitis virus 
(LCMV) and vaccinia virus and also after peptide immunization or exposure to alloantigens.36‑41 
The overall conclusion from these experiments is that functional immune responses do occur in 
Figure 1. The IL‑2 receptor (IL‑2R) and its subunits. IL‑2Rs are either dimeric IL‑2Rαβ and bind 
IL‑2 with a low affinity (Kd ∼10-9 M) or trimeric IL‑2Rαβγ and associate with IL‑2 with a Kd of 
about 10-11 M. IL‑2Rα (α subunit), also called CD25, is the private α chain of IL‑2 and does not 
bind any other cytokine. Moreover, CD25 does not contain a cytoplasmic tail and thus is not 
involved in signaling. Conversely, IL‑2Rβ (β subunit, also called CD122) and IL‑2Rγ (γ subunit, 
also known as the common gamma chain, γc, or CD132) are crucial for signal transduction upon 
IL‑2 binding to the IL‑2R. CD122 is also a receptor subunit of the IL‑15R, whereas γc is shared 
by all γc cytokines, i.e., IL‑2, IL‑4, IL‑7, IL‑9, IL‑15 and IL‑21. Downstream signaling is mediated 
by the Jak‑STAT pathway, notably involving Jak1, Jak3 and STAT5 as well as STAT3.
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IL‑2–/– mice, but these responses are somewhat lower and less robust than in normal mice. The 
results are as follows; the shortcoming of the use of IL‑2‑deficient mice is discussed later.
In comparison to IL‑2+/– heterozygous or wild‑type (WT) control mice, IL‑2–/– animals gave 
near‑normal CD8+ T‑cell effector responses as measured by direct ex vivo cytotoxicity upon infection 
with vaccinia virus.36,37 For infection with LCMV, a 3‑fold decrease of cytotoxic T‑lymphocyte (CTL) 
activity was noted in comparison to control mice when spleen cells from IL‑2-/- mice were tested in 
a direct ex vivo cytotoxicity assay.36‑39 Moreover, spleen cells from IL‑2-/- mice produced markedly 
reduced interferon (IFN)‑γ and IL‑4 levels upon in vitro restimulation for 24 h.38,39 Two studies 
concluded that these differences were not biologically significant because IL‑2-/- mice infected with 
LCMV were as efficient as IL‑2+/- or WT mice in mounting a delayed‑type hypersensitivity response 
(as measure by footpad‑swelling reaction), clearing LCMV below detection levels from spleens, livers 
and kidneys by days 9‑10 and protection against lethal choriomeningitis after intracerebral infec‑
tion with LCMV.36,37 Conversely, others came to a different conclusion, reporting that IL‑2-/- mice 
infected with LCMV contained detectable virus in the spleen and especially in the kidneys on day 7 
after infection, whereas IL‑2‑competent control mice had cleared LCMV from these organs by that 
time.38 These disparate findings may reflect the different doses of LCMV and routes of administration 
(300 plaque‑forming units (PFU) intravenously vs. 2000 PFU intraperitoneally, see Table 1) used 
Figure 2. Expression levels of IL‑2 and IL‑2R subunits and the role of IL‑2 during the different phases 
of a CD8+ T‑cell immune response. Following activation by a professional APC, naïve CD8+ 
T‑cells start to proliferate and expand. Proliferation is considerably enhanced by the concomitant 
production of IL‑2 (solid line), which initially binds to low‑affinity IL‑2Rαβ receptors and, upon 
upregulation of CD25 (dotted line), to high‑affinity IL‑2Rαβγ receptors. Notably, CD122 (dashed 
line) is also upregulated during expansion and is highest on memory T‑cells, where it serves 
mainly for conferring responsiveness to IL‑15. The role of endogenous IL‑2 during activation and 
proliferation of CD8+ T‑cells is to optimize cell expansion; by contrast, contact with exogenous 
IL‑2 during this phase does not seem to be necessary or beneficial. During the contraction phase, 
however, administration of exogenous (recombinant) IL‑2 is highly beneficial in preventing cell 
death and thus allowing higher numbers of antigen‑specific T‑cells to survive as memory cells 
for several months. Endogenous IL‑2 seems to be dispensable for CD8+ T‑cell survival during the 
contraction phase. For memory CD8+ T‑cells, homeostatic proliferation of these cells is augmented 
by the presence of endogenous IL‑2 or the administration of exogenous IL‑2.
©
20
09
 C
op
yr
ig
ht
 L
an
de
s B
io
sc
ie
nc
e. 
N
ot
 fo
r D
ist
rib
ut
io
n
5The Role of Interleukin-2 in Memory CD8 Cell Differentiation
in these studies. Whether this roughly 7‑fold difference in initial viral load along with the dissimilar 
routes of infection could explain the differences observed remains to be tested.
Others found that IL‑2 signals affected the expansion of antigen‑specific CD8+ T‑cells only in 
nonlymphoid tissues (such as in lamina propria, epithelia, liver and lungs) but not in lymphoid 
organs such as the spleen. Thus, after adoptive transfer of IL‑2-/- ovalbumin‑specific OT‑I TCR 
transgenic (tg) CD8+ T‑cells to IL‑2-/- vs. WT mice followed by subsequent infection with 
recombinant vesicular stomatitis virus expressing ovalbumin, the authors found that paracrine 
IL‑2 signals significantly increased the survival and sustained expansion of antigen‑specific CD8+ 
T‑cells in nonlymphoid tissues but not in spleen; paradoxically, autocrine IL‑2 signals (observed 
with WT tg cells) negatively influenced expansion in nonlymphoid tissues.42,43 In another study, 
Listeria monocytogenes (LM)‑specific TCR tg CD8+ T‑cells transferred to WT hosts underwent 
comparable expansion and production of IFN‑γ after infection with LM regardless of whether 
the donor antigen‑specific CD8+ T‑cells were from an IL‑2-/- or WT genetic background, thus 
providing further evidence that autocrine IL‑2 was not essential for in vivo CD8+ cell expansion 
and IFN‑γ production in response to LM.44 However, the responding CD8+ T‑cells were still able 
to receive paracrine IL‑2 signals in both situations.
Besides these above‑mentioned studies on viral and bacterial infections, IL‑2-/- mice were also 
used to test the role of IL‑2 in CD8+ responses to alloantigens. In one study, IL‑2-/- vs. IL‑2+/- and 
WT mice were rendered diabetic before transplantation with allogeneic islets grafts; allograft 
function was then followed by monitoring blood glucose measurements. The results showed that 
IL‑2-/- mice were able to reject islet allografts, albeit with delayed kinetics compared to IL‑2+/- or 
WT mice.40 Similarly, in another study, vascularized cardiac allografts were rejected by IL‑2-/- mice, 
though here rejection was as rapid as with WT mice.41
The contribution of IL‑2 to CD8+ T‑cell responses has also been tested with the aid of CD25-/- 
mice. In the absence of CD25, IL‑2 is able to bind to and signal by the dimeric IL‑2Rβγ receptor,45,46 
even though such binding is around 100‑fold weaker than to the trimeric high‑affinity IL‑2Rαβγ 
complexes.31‑33 To examine the influence of CD25, CD25-/- vs. WT OT‑I TCR tg CD8+ T‑cells 
were transferred to WT recipients, which then received either recombinant vesicular stomatitis 
virus expressing ovalbumin, soluble ovalbumin or tumor cells expressing ovalbumin. These ex‑
periments showed that IL‑2 signaling through high‑affinity IL‑2Rs was not important for initial 
division of the responding CD8+ cells, even though CD25 was upregulated on WT OT‑I cells 
before the first division; however, IL‑2 was necessary for optimal expansion and sustained survival 
of the responding cells.43 Interestingly, CD8+ tg T‑cells engineered to be capable of prolonged 
IL‑2R‑mediated signaling showed a significant increase in expansion of CD8+ cells in response to 
LCMV, followed by enhanced secondary responses upon re‑exposure to antigen.47
Contrasting in part with these above‑mentioned findings on IL‑2, another study implicated an 
initial role for IL‑15 in CD8+ cell proliferation. This study examined polyclonal T‑cell responses to 
alloantigens or superantigens in vivo and concluded that IL‑15‑driven initial cell division had to 
occur before IL‑2 production; IL‑2 synthesis and CD25 upregulation became evident towards the 
end of the T‑cell expansion phase and IL‑2 signaling during this stage decreased or even terminated 
T‑cell proliferation via downregulation of the γc receptor.48 For anti‑viral responses, however, there is 
no evidence for downregulation of the γc receptor.49 Moreover, administration of recombinant IL‑2 
(rIL‑2) promotes the expansion of CD8+ cells,43,49 indicating that levels of γc receptors on the respond‑
ing CD8+ T‑cells are sufficient for IL‑2 signaling. These data thus question the notion of a negative 
role for IL‑2 at the end of the T‑cell expansion phase because of γc downregulation. T‑cell expansion 
is probably curtailed largely through loss of contact with antigen at the end of the primary response, 
thus leading to a decrease in the stimulus for IL‑2 production. However, a decline in IL‑2 produc‑
tion may also involve other factors. Here, it is noteworthy that the factor B‑lymphocyte‑induced 
maturation protein 1 (BLIMP1), a transcriptional repressor, has been suggested to regulate terminal 
differentiation of effector T‑cells by limiting IL‑2 production and promoting activation‑induced 
cell death (AICD).50‑52
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8 Memory T-Cells
It is important to note the shortcomings associated with the use of IL‑2-/- and IL‑2R-/- mice. In 
particular, these mice develop hyperplasia of secondary lymphoid organs along with a multi‑organ 
inflammatory disease, thus partly obscuring other immune responses.53‑55 Moreover, T‑cells devel‑
oping in these animals do not receive any (or modified) IL‑2 signals and develop in the absence of 
IL‑2‑dependent Tregs. In order to circumvent these problems, investigators have used a BM chimera 
approach where irradiated WT mice were reconstituted with a mixed population of T‑cell‑depleted 
BM from WT and CD25-/- mice, thus allowing a direct comparison of normal and CD25‑deficient 
CD8+ cell responses in a normal host. Subsequently, these mixed chimeras were infected with LCMV 
and virus‑specific CD8+ T‑cells from WT or CD25-/- origin and analyzed based on differential 
expression of congenic markers. One group of researchers observed only minimal differences in the 
responses of the two populations of CD8+ T‑cells during primary expansion, regardless of whether 
polyclonal CD8+ T‑cells or LCMV‑specific TCR tg CD8+ T‑cells were tested.46 Conversely, also 
using LCMV infection (but another LCMV strain), others reported a 5‑fold decrease in the primary 
expansion of CD25-/- polyclonal CD8+ T‑cells as compared to their WT counterparts.56 IL‑2 signals 
through high‑affinity IL‑2Rs might thus be important for maximal expansion of virus‑specific CD8+ 
T‑cells. This finding is in line with the above data obtained using IL‑2-/- mice.
Another approach for countering the severe pathology seen in IL‑2-/- and IL‑2R-/- mice is to limit 
IL‑2 unresponsiveness selectively to peripheral T‑cells but not thymocytes. This has been done by 
generating CD122-/- tg mice that express CD122 under the CD2 promoter, thus leading to selective 
expression in thymocytes;57 these mice do not display pathology and show normal CD8+ cell develop‑
ment. With these mice, it was shown that signals through CD122 (the common receptor for IL‑2 and 
IL‑15) were dispensable for generating expansion and CTL activity of CD8+ T‑cells following in vivo 
infection with recombinant vaccinia virus, injection of an agonistic anti‑CD3 mAb or stimulation 
with superantigen.57,58 Nevertheless, IFN‑γ production was somewhat reduced, indicating that optimal 
stimulation required signaling through CD122.57,58 Others obtained similar findings by preparing 
OT‑I TCR tg CD8+ T‑cells on a WT, CD122-/- or CD122–/– tg background and then transferring 
these cells to WT mice followed by administration of soluble ovalbumin; based on proliferation 
and generation of CTL activity in vivo, no significant difference was noted in antigen‑specific CD8+ 
T‑cells from these different backgrounds.59 These results with CD8+ cells from CD122-/- tg mice 
contrast with the above data obtained by others using IL‑2-/- and CD25-/- mice.
The various approaches described above were aimed at determining the role of endogenous 
IL‑2 at normal physiological levels. The results of exposing CD8+ cells to exogenous IL‑2 are 
considered below.
The effects of administering low‑dose recombinant human (rh) IL‑2 during expansion of 
virus‑specific CD8+ T‑cells was examined by giving mice two injections per day of 15,000 inter‑
national units (IU) of rhIL‑2 on days 0‑8 after LCMV infection. Such IL‑2 treatment resulted 
in similar LCMV‑specific CD8+ T‑cell counts in IL‑2‑treated and control mice on day 8 after 
infection (though, surprisingly, numbers of virus‑specific CD4+ T‑cells at the peak of the response 
were markedly reduced in IL‑2‑treated mice compared to controls).49 Moreover, IL‑2 treatment 
did not affect LCMV clearance from the spleen and viral titers became undetectable 9 days after 
infection in both groups. These results suggest that provision of additional IL‑2 during the first 8 
days following LCMV infection does not influence primary expansion and effector function of 
virus‑specific CD8+ T‑cells (which contrasts with a negative influence on virus‑specific CD4+ cells). 
Interestingly, allospecific responses of 2C TCR tg CD8+ T‑cells to BALB/c (H‑2d) splenocytes 
were found to be increased by about 40% following the administration of recombinant mouse (rm) 
IL‑2 during the first 4 days of stimulation in vivo.60 Moreover, for total T‑cells stimulated with 
superantigens, implantation of an IL‑2‑containing osmotic pump prolonged the expansion and 
survival of superantigen‑reactive T‑cells as measured on day 6 after stimulation.61 Thus, provision 
of exogenous IL‑2 in these latter two settings might be beneficial because, under the conditions 
used, immune activation to alloantigens or superantigens was brief in the absence of IL‑2 and 
therefore probably associated with much less proliferation than after virus infection. In the case 
of alloantigens, prolonged anti‑host responses occur when T‑cells are transferred to irradiated 
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9The Role of Interleukin-2 in Memory CD8 Cell Differentiation
H‑2‑different mice, thus eliciting graft‑versus‑host disease (GVHD). For GVHD produced by 
purified CD8+ cells, disease induction is much worse when the hosts are injected repeatedly with 
rIL‑2 starting at 1 week posttransfer or when donor CD8+ cells are co‑injected with IL‑2‑producing 
CD4+ cells.62 Paradoxically, with a mixed population of T‑cells, administration of IL‑2 from days 
0‑5 after T‑cell transfer can protect against GVHD, perhaps by stimulating Tregs.63
Recently, it has been shown that naïve CD8+ T‑cells can proliferate vigorously and differentiate 
into MP cells when exposed to high levels of IL‑2 in vivo in the absence of antigen. Such prolifera‑
tion occurs when naïve CD8+ cells are transferred to CD25-/- or CD122-/- mice; not being able 
to utilize IL‑2, these mice have high levels of IL‑2 and also IL‑15 in the case of CD122-/- mice.64 
Antigen‑independent proliferation of naïve CD8+ cells to IL‑2 also occurs after administration of 
rIL‑2 mixed with a particular anti‑IL‑2 monoclonal antibody (mAb).45 This combination leads to 
the formation of highly stimulatory IL‑2/anti‑IL‑2 mAb complexes, which under in vivo condi‑
tions are able to stimulate polyclonal or TCR tg naïve CD8+ T‑cells to differentiate into effector 
cells able to produce IFN‑γ, tumor necrosis factor‑α and granzyme B as well as lysis of target 
cells.64,65 Subsequently, these IL‑2/anti‑IL‑2 mAb complex‑stimulated CD8+ cells differentiated 
into MP cells (for polyclonal cells) or central memory cells (in the case of TCR tg cells). For TCR 
tg cells, OT‑I memory CD8+ cells generated by activation with IL‑2/anti‑IL‑2 mAb complexes 
in the absence of antigen conferred efficient protection against challenge with recombinant LM 
expressing ovalbumin.65 Notably, despite being antigen independent, this form of IL‑2‑driven 
proliferation of naïve CD8+ cells was found to be highly dependent on contact with self‑peptide/
MHC‑I molecules, i.e., as for naïve CD8+ cells undergoing IL‑7‑driven homeostatic expansion. 
It should be noted that IL‑2/mAb complexes also considerably enhance antigen‑driven responses. 
Thus, when IL‑2/anti‑IL‑2 mAb complexes were injected plus specific antigen to stimulate 
influenza‑specific TCR transgenic CD8+ T‑cells in vivo, the complexes increased numbers of 
proliferating antigen‑specific CD8+ cells by 7‑fold and conferred the cells with strong effector 
functions such as IFN‑γ production and CTL activity.66
IL‑2 and the Contraction Phase
As mentioned earlier, most effector cells are eliminated at the end of the primary response, thus 
leading to a sharp contraction in total numbers of antigen‑reactive cells. When BM chimeras con‑
taining a mixture of WT and CD25-/- cells were infected with LCMV, the decline in virus‑specific 
CD8+ cell numbers during the contraction phase was similar for WT and CD25-/- cells.46 Thus, 
IL‑2 signals via the high‑affinity IL‑2R do not seem to influence contraction. By contrast, injec‑
tion of IL‑2 during the contraction phase does prevent elimination of the responding cells. Thus, 
treating mice twice daily with 15,000 IU rhIL‑2 on days 8‑15 after LCMV infection resulted in a 
marked reduction of T‑cell apoptosis and increased survival, both for CD8+ and CD4+ cells.49 This 
effect was seen in both lymphoid and nonlymphoid organs (such as liver and lungs), indicating that 
IL‑2 had a direct effect in promoting cell survival rather than causing an alteration in cell migration. 
Following this short course of IL‑2 therapy for 1 week, elevated numbers of LCMV‑specific CD8+ 
and CD4+ cells persisted for about 6 months before reaching the levels found in control mice. This 
potentiating effect of IL‑2 on CD8+ T‑cell counts was not a byproduct of the increase in CD4+ num‑
bers but reflected a direct action of IL‑2 on CD8+ cells: thus, the beneficial effect of IL‑2 on CD8+ 
cell numbers also applied in mice lacking CD4+ T‑cells (either following depletion of CD4+ T‑cells 
by antibody in normal mice or by using CD4-/- mice).49 On a per‑cell basis, the CD8+ cells from 
IL‑2‑treated mice were roughly as efficient as their counterparts from control animals. Collectively, 
these experiments suggest that IL‑2 therapy during the contraction phase of an anti‑viral immune 
response results in increased immunity to virus that lasts for several months (Fig. 2).
Similar findings on the beneficial role of exogenous IL‑2 during the contraction phase were 
observed for the response of OT‑I TCR tg CD8+ T‑cells to soluble ovalbumin or recombinant 
vesicular stomatitis virus expressing ovalbumin. Here, daily injections of IL‑2 during the later stages 
of the primary response prevented elimination of the responding cells, although this effect lasted 
only for 1‑2 weeks.43,59
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Memory Cell Generation and Recall Responses
During expansion and proliferation of antigen‑specific T‑cells a small subset of cells expresses high 
levels of IL‑7Rα (also called CD127); these cells give rise to long‑lived memory cells, suggesting a 
role for IL‑7 signals in the generation of functional memory cells.67
Recently, it was shown that IL‑2 signals received during priming are necessary for efficient sec‑
ondary responses of CD8+ T‑cell to viruses (Fig. 2).46,56 Thus, for the above‑mentioned mixed WT/
CD25-/- BM chimeras, it was reported that LCMV‑specific memory CD8+ T‑cells of CD25-/- origin 
expanded only 4‑fold upon secondary antigen challenge 150 days after primary infection, compared 
to 40‑fold expansion of WT memory CD8+ cells.46 Another group showed a 30‑ to 40‑fold reduc‑
tion in secondary expansion of CD25-/- antigen‑specific CD8+ T‑cells, relative to WT cells, when 
measured 30‑45 days after primary antigen challenge.56 This defect was not due to impaired primary 
expansion or decreased homeostatic proliferation during the memory phase, although total numbers 
of virus‑specific CD25-/- memory CD8+ T‑cells were 2‑ to 5‑fold reduced in comparison to their 
WT counterparts. Instead, the failure to mount an efficient secondary response following challenge 
was due to a lack of IL‑2 signals during priming. Thus, injection of IL‑2 in the form of IL‑2/anti‑IL‑2 
mAb complexes45 during the primary response allowed virus‑specific CD25–/– memory CD8+ T‑cells 
to efficiently expand and survive following secondary antigen challenge;46 injecting IL‑2 during the 
secondary response, by contrast, was much less effective. Given that IL‑2 acts through low‑affinity 
IL‑2Rs (CD122) on CD25-/- CD8+ cells, it would be interesting to test whether enhanced levels 
of IL‑15 could substitute for IL‑2 in rescuing secondary responses of CD25-/- CD8+ T‑cells. In this 
respect, the poor generation of memory by CD25–/– CD8+ T‑cells also applies to normal CD8+ cells 
primed in the absence of CD4+ T‑cells.68‑70 As CD4+ T‑cells are the main producers of IL‑2 under 
steady‑state conditions,25 these findings consolidate the view that the optimal function of memory 
cells hinges on the precursors of these cells being exposed to IL‑2 during initial priming. It should be 
mentioned that CD8+ T‑cells themselves can produce significant amounts of IL‑2 in viral infections, 
but presumably in amounts insufficient to replace the need for IL‑2 “help” from CD4+ cells.71
With regard to resting memory CD8+ cells, it was mentioned earlier that these cells divide 
sporadically through contact with background levels of IL‑15. As for MP cells, the turnover of 
antigen (LCMV)‑specific memory CD8+ (and CD4+) cells is considerably enhanced following 
injection of exogenous IL‑2 (or IL‑15).49 Since memory and MP cells have low expression levels of 
CD25, responsiveness of these cells to IL‑2 (and IL‑15) is mediated by low‑affinity IL‑2Rs.45
As for acute viral infection, IL‑2 therapy can also lead to an increased frequency of virus‑spe‑
cific CD8+ T‑cells during chronic viral infections. Thus, when mice infected with LCMV 
clone 13, which results in a chronic infection, were treated with low‑dose rhIL‑2 for 1 week, 
LCMV‑specific CD8+ cell counts increased by about 10‑fold and serum viral titers decreased 
in 80% of the animals.49 This efficient stimulation of CD8+ cells by IL‑2 is somewhat surpris‑
ing as CD8+ T‑cells found in chronic infections have only intermediate levels of CD122 and 
background levels of CD25 receptors,72 which contrasts with the high levels of CD122 found 
on normal MP CD8+ cells and memory CD8+ T‑cells generated after acute LCMV infection.19,73 
Notably, the LCMV‑specific CD25-/- CD8+ T‑cells generated in mixed WT/CD25–/– BM 
chimeras declined rapidly during persistent viral infection.56 Thus, for chronic viral infections, 
either exogenous or endogenous IL‑2 signals seem to be beneficial or even crucial for the pro‑
longed maintenance of the responding CD8+ T‑cells; these signals have to be delivered through 
high‑affinity IL‑2Rs.56
Memory Maintenance and Homeostasis
As mentioned before, the few CD8+ T‑cells surviving the contraction phase and becoming 
resting memory cells are kept alive and in occasional cell division through contact with IL‑15 and 
IL‑7; these cells do not need TCR interaction with self‑peptide/MHC‑I molecules.13‑15 Currently, 
there is minimal evidence that IL‑2 has a direct role in memory maintenance or homeostasis, 
probably because the background levels of IL‑2 are too low to affect resting cells. Nevertheless, 
it is notable that antigen‑specific CD8+ memory cells generated in the absence of CD4+ T‑cells 
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11The Role of Interleukin-2 in Memory CD8 Cell Differentiation
gradually decrease during the memory phase.69,70 This decrease might be due to a lack of CD4+ 
cell‑derived IL‑2 signals. Interestingly, CD8+ MP cells adoptively transferred to IL‑2-/- recipients 
show a slightly reduced rate of homeostatic proliferation compared to WT recipients (O.B. and 
J.S., unpublished data). Hence, contact with endogenous IL‑2 may play a significant, if minor role 
in memory CD8+ cell homeostasis. As mentioned above, memory and MP CD8+ cells are both 
strongly responsive to exogenous IL‑2 signals.45,49
Indirect Roles of IL‑2 in the Generation of Memory CD8+ T‑Cells
Through its role in controlling the survival of CD4+ Tregs, IL‑2 plays a vital role in maintain‑
ing immune tolerance.22,25,74,75 Tregs, which are typified by high expression of CD25 and forkhead 
box p3 (Foxp3) transcription factor,34,76‑78 may impair memory cell generation indirectly by several 
mechanisms, including inhibiting the intensity of the primary response, secreting inhibitory cy‑
tokines and consuming stimulatory cytokines, including IL‑2.79‑83 The many inhibitory functions 
of Tregs on the immune response have been discussed elsewhere.84‑87
Concluding Comments
In conclusion, IL‑2 seems to have an important influence on CD8+ cells at all stages of the immune 
response. Nevertheless, the evidence on this issue is still fragmentary and there are still substantial 
points of disagreement. For the primary response, most studies indicate that IL‑2 is needed for opti‑
mal expansion and generation of effector functions. The discrepancies observed between individual 
studies may reflect the different systems used (pathogen vs. peptide stimulation) and/or differences 
in the precursor frequencies of antigen‑specific CD8+ T‑cells: thus, systems with high frequencies of 
responding antigen‑specific CD8+ cells may consume large amounts of stimulatory cytokines, thus 
accentuating a need for IL‑2 for optimal expansion. Alternatively, as suggested by some studies,43,48 
IL‑2 might not be necessary for initial division of CD8+ cells but rather for the late stages of prolif‑
eration, thus accentuating the overall magnitude of the primary response and thereby increasing the 
total numbers of effector cells available for differentiation into early memory cell precursors.35 Since 
90‑95% of antigen‑specific T‑cells disappear by apoptosis during the contraction phase—perhaps 
largely because of loss of contact with growth factors—exposure to exogenous IL‑2 during this stage 
can be highly beneficial in promoting cell survival and differentiation into early memory cells. Once 
these precursor cells upregulate CD122 and re‑express IL‑7Rα, memory cells become sensitive to 
the stimulatory effects of IL‑15 and IL‑7, IL‑15 inducing intermittent cell division and IL‑7 control‑
ling survival.9,10,19,45 At this stage, administration of exogenous IL‑2 is able to boost the frequency of 
memory T‑cells, especially CD8+ memory cells.45,49 It is notable that IL‑2 therapy is able to enhance 
proliferation of virus‑specific CD8+ T‑cells during the contraction phase but not during initial ex‑
pansion. Why exogenous IL‑2 is generally ineffective during the expansion phase is unclear. A likely 
possibility is that, during this stage, the stimulatory effects of IL‑2 are countered by various negative 
influences, including enhanced sensitivity to BLIMP1‑mediated AICD and suppression through 
the activation of Tregs.51,52 Overall, IL‑2 signals can be viewed as fine‑tuning the immune response, 
boosting weak responses and inhibiting excessive responses, thus promoting an optimal response that 
eliminates the pathogen concerned while maintaining normal self‑tolerance.
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